|
Molecular Epidemiology of Parkinson's Disease Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Molecular Epidemiology of Parkinson's Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Molecular Epidemiology of Parkinson's Disease Clinical research trials and Molecular Epidemiology of Parkinson's Disease healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Molecular Epidemiology of Parkinson's Disease. Molecular Epidemiology of Parkinson's Disease Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Molecular Epidemiology of Parkinson's Disease clinical trial. Subjects frequently obtain the most expert healthcare possible for their Molecular Epidemiology of Parkinson's Disease condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Molecular Epidemiology of Parkinson's Disease  Molecular Epidemiology of Parkinson's Disease
Molecular Epidemiology of Parkinson's Disease
For Condition: Parkinson Disease
Status: Recruiting
Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) ,
Synopsis: The aim of this research is to discover genes which modify risk for Parkinson's disease. The study includes 800 patients with Parkinson's disease, and their estimated 1,222 available siblings. Common variations of at least 9 genes will be studied, including genes associated with personality, substance use, and anxiety and depression.
Details: Parkinson’s disease (PD) is a common and disabling condition in the expanding elderly population of the US and worldwide. Its etiology remains unknown and both genetic and environmental factors have been suspected. The long-term goal of the proposed studies is to clarify the etiology of PD and to identify means to prevent it. Specifically, we will study the association of PD with susceptibility genes previously found associated with novelty seeking behavior, substance use (tobacco, alcohol, and caffeine), and anxiety and depressive disorders. The hypotheses tested derive directly from our current work and preliminary findings. We will employ the case-unaffected sibling control study design and analyses will use a generalization of the sibling transmission dysequilibrium test, or “S-TDT”. In total, nine candidate susceptibility genes will be considered, of which only five have undergone limited study for PD. The candidate susceptibility genes include three detoxification genes, three dopaminergic genes, and three serotonergic genes. We will include 800 cases of PD referred to the Mayo Clinic from a 120-mile radius or from a 5-state region during approximately a 10-year period. We will also include their eligible siblings age 40 years or above, projecting that blood DNA samples will be available for 563 affected probands or siblings and 1,180 unaffected siblings stratified in 521 informative sibships. Sibships with multiple affected or unaffected siblings will be included. PD cases will undergo a clinical assessment and blood sampling, and provide family information through a face-to-face interview followed by a written mail-in form. All living siblings ages 40 and above will be screened for PD using a validated telephone instrument. Subjects screening negative for PD will provide DNA with mail-in blood sampling kits only. Persons screening positive will be clinically assessed at the Mayo Clinic or at home, and blood DNA samples will be directly obtained. Genotyping will be performed using polymerase chain reaction methods and will be blinded to affected or unaffected status. The study will avoid population stratification bias by using sibling controls. The candidate susceptibility genes selected for primary analyses relate to personality traits, substance use, and psychiatric diseases that we have found associated with PD. The selection of these genes represents a major paradigm shift. We will also establish a large DNA bank for rapid and efficient testing of new genetic hypothesis for PD. This application is submitted in response to RFA ES-00-002 (“The Role of the Environment in Parkinson’s Disease”). We specifically address the RFA’s objectives of evaluating endogenous (including biomarkers) and exogenous (including dietary and lifestyle) susceptibility factors for PD using molecular epidemiology tools.
Eligibility:
Study Type: Observational,Natural History,Cross-Sectional,Defined Population,Retrospective/Prospective Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients with Parkinson's disease recruited from the Department of Neurology, Mayo Clinic, Rochester MN, residing in MN or the surrounding 4 states (WI, IA, SD, ND); their siblings above age 40.
Total Enrollment: 2022
Location and Contact Information:
Overall Study Official:
DemetriusMaraganore, Principal Investigator, Department of Neurology, Mayo Clinic Rochester
Department of Neurology, Mayo Clinic *Recruiting*
Rochester, Minnesota, 55905
United States
Recruiting Demetrius Maraganore 507-280-8717
Additional Information:
Study ID Numbers: 10751-CP-001;
Study Start Date: September 2000
Record last reviewed: July 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00042107
Other Parkinson Disease Studies:
1. Phase II Study of Pallidotomy for Parkinson Disease
2. The Role of Dopamine in Motor Learning in Healthy Subjects and Patients with Parkinson's Disease
3. An Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability, and Therapeutic Response In Patients with Parkinson's Disease with an Investigational Drug
4. A Clinical Study to Evaluate a New Investigative Drug for the Treatment of Parkinson's Disease
5. Investigating the Safety of srTMS in the Treatment of Parkinson's Disease
Related Studies:
Other Parkinson Disease Clinical Trials
Other Minnesota Clinical Trials
Other Rochester Clinical Trials
Molecular Epidemiology of Parkinson's Disease
|
|
|
|
|
|
|
|
